European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
The Brighterside of News on MSN20m
Weight-loss drug Semaglutide could significantly reduce the risk of heart attacksA new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...
CINCINNATI ( WXIX /Gray News) - A 7-year-old is in a hospital in Ohio fighting for her life after experiencing her second heart failure. Nyla Pritchett has been at Cincinnati Children’s Hospital since ...
In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...
Hope Unlimited Ministries will have its annual fundraising event featuring Point of Grace on Thursday, Oct. 17. This event ...
Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In ...
Pregnancy-Related Heart Failure Is Under-Detected; AI-Enabled Stethoscope Helped Doctors Diagnose Twice as Many Cases Sep. 3, 2024 — Heart failure during pregnancy is a dangerous and often ...
The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.
Heart failure arises when the heart cannot pump blood efficiently, leading to symptoms such as shortness of breath and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback